Targeted DNA RNA Sequencing Market Size, Share & Trends Analysis Report By Technology (NGS, Application, Others), By Workflow (Pre-sequencing, Sequencing, Data Analysis), By Application (Human Biomedical Research, Plant & Animal Sciences, Drug Discovery, Others), By Type (DNA-Based Targeted Sequencing, RNA-Based Targeted Sequencing), By End Use (Academic Research, Hospitals & Clinics, Pharma & Biotech Entities, Other Users) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Targeted DNA RNA Sequencing Market Size & Growth Analysis

The global targeted dna rna sequencing market size was valued at USD 9.35 billion in 2025 and is projected to grow from USD 11.12 billion in 2026 to USD 44.68 billion by 2034, registering a CAGR of 18.98% during the forecast period from 2026 to 2034. North America dominated the targeted dna rna sequencing market with a market share of 44.34% in 2025.

The targeted DNA RNA sequencing market encompasses technologies and workflows designed to selectively analyze defined genomic and transcriptomic regions rather than entire genomes, enabling focused detection of variants, gene expression patterns, fusions, and microbial signatures with higher depth and interpretive clarity. This market includes NGS-based methods such as exome sequencing, enrichment panels, and amplicon assays, as well as applications spanning cancer gene profiling, inherited disease analysis, drug development, forensic genomics, and microbial sequencing. It further comprises pre-sequencing preparation steps, sequencing operations, and downstream data analysis pipelines that support precise characterization of selected genomic intervals. End users include academic research institutes, hospitals and clinics, pharmaceutical and biotechnology companies, and assorted laboratory groups that employ targeted sequencing to advance diagnostics, research programs, and therapeutic development.

Technology Insights

The NGS method category dominates the market in 2025 as exome sequencing, enrichment sequencing, amplicon sequencing and related approaches account for the largest contribution due to their capacity to focus on defined genetic regions while maintaining high analytical detail across clinical and research environments. Their extensive placement across sequencing centers supports broad adoption across oncology studies, inherited condition assessments and transcript-focused investigations where targeted outputs are required.

The Others technology category records the fastest expansion with a 19.12% growth rate as laboratories incorporate flexible targeted platforms for microbial studies, metagenomic investigations and specialized genomic assays. The entry of adaptable systems capable of supporting distinct sequencing priorities accelerates uptake across institutions expanding targeted workflows beyond conventional clinical areas.

Request Customizationto receive a tailored report.

Workflow Insights

The sequencing phase dominates the workflow structure with a 57.31% share in 2025 supported by its central role in producing region-specific reads used for downstream variant classification and transcript evaluation. Continuous installation of sequencing units across diagnostic labs and genomic research facilities reinforces the position of the sequencing phase as the core operational step within targeted workflows.

Data analysis represents the fastest-growing workflow stage at 19.78% as rising sequencing volumes across research and medical centers increase demand for computational interpretation pipelines. Adoption of automated analytics frameworks and scalable cloud systems enhances processing capacity for variant calling, expression quantification, and panel-based dataset management.

Application Insights

Human biomedical research dominates the application landscape with a 69.12% share as targeted sequencing remains central to projects that investigate disease-linked alterations, pathway-level changes, and gene expression variations across human samples. Widespread integration of targeted assays into studies on cancer progression, genetic disorders, and clinical biomarkers firmly positions this segment at the forefront of market contribution.

Drug discovery is the fastest growing application with a 19.35% rate driven by increased use of targeted DNA and RNA panels for lead identification, mechanistic exploration, and early-stage candidate evaluation. Pharmaceutical pipelines integrate targeted sequencing to refine decision-making during preclinical development and strengthen precision-oriented therapeutic strategies.

Type Insights

DNA-based targeted sequencing dominates the type category in 2025 due to its broad use in mutation assessment, genomic profiling, and focused region analysis. Its placement across oncology diagnostics, hereditary disease testing, and specialized research programs supports extensive utilization throughout diverse sequencing environments.

RNA-based targeted sequencing is the fastest growing type with a 19.56% rate as laboratories expand transcript-level investigations, including fusion detection, expression monitoring and pathway activity studies. Increased deployment across immunology, oncology, and neurological research reinforces the rapid upward trajectory of this segment.

End Use Insights

Hospitals and clinics dominate the end-use category with a 45.12% share driven by escalating adoption of targeted sequencing for cancer diagnostics, inherited disease confirmation and treatment planning. Expanded installation of sequencing facilities within healthcare systems enables streamlined use of targeted panels in routine medical evaluation.

Pharma and biotech entities mark the fastest growth rate at 19.22% as research divisions incorporate targeted sequencing for biomarker validation, therapeutic assessment, and companion diagnostic exploration. Integration of sequencing into R&D pipelines strengthens reliance on targeted assays to support drug development initiatives.

Speak to an Analystto discuss market opportunities.

Regional Analysis

North America leads the targeted DNA RNA sequencing market in 2025 with a large revenue share of 44.34% driven by extensive adoption of sequencing technologies across clinical genomics networks and academic centers. Expanding investments in precision medicine programs across the region strengthen sequencing workflows and expand access to targeted assays for oncology infectious disease research and hereditary disorder screening.

The U.S. market advances due to federal commitments toward nationwide genomic surveillance and large-scale sequencing data programs. Government allocations exceeding USD 3.6 billion across genomics driven healthcare initiatives accelerate the adoption of targeted DNA and RNA panels in hospitals, research centers and biopharma programs, enhancing the country’s role as a core driver of global sequencing activity.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia Pacific Market Insights

Asia Pacific records the fastest growth rate of 20.98% during the forecast period, supported by rapid expansion of genomics facilities across China, India, and Australia. The region is witnessing strong uptake of targeted sequencing assays as healthcare systems integrate molecular diagnostics into population health and clinical research programs.

China’s market accelerates due to the broad establishment of sequencing clusters backed by a national initiative valued at RMB 210 billion focused on scaling genomic medicine and expanding local reagent manufacturing, which boosts the availability of targeted DNA and RNA sequencing tools across clinical and research environments.

Europe Market Insights

Europe maintains steady growth supported by broad public sector commitments to genomic science and translational medicine. Regional research institutes and diagnostic laboratories are expanding targeted sequencing capabilities to support oncology screening, rare disease analysis, and microbiological investigations.

Germany records rising adoption fueled by federal and state-level programs that allocated more than USD 1.2 billion in 2024 to create connected genomic data networks, which strengthen procurement of targeted sequencing panels across hospitals and research consortia.

Latin America Market Insights

Latin America experiences rising demand driven by the expansion of clinical molecular testing capacity across Brazil, Mexico, and Chile. Growing emphasis on early disease detection and genetic analysis supports increased use of targeted sequencing assays in oncology, infectious disease evaluation, and population studies.

Brazil’s market grows due to new national directives allocating roughly USD 520 million toward genomics infrastructure, which expands local sequencing throughput and encourages procurement of targeted DNA and RNA kits across public and private laboratories.

Middle East and Africa Market Insights

The Middle East and Africa region registers steady development supported by growth in molecular diagnostic laboratories in Saudi Arabia, the United Arab Emirates, Kenya, and South Africa. Increasing governmental focus on improving genetic testing pathways strengthens the adoption of targeted sequencing across clinical and academic sectors.

Saudi Arabia advances due to national healthcare modernization efforts that funded more than USD 350 million for genomics and molecular testing programs, which expand sequencing installations and widen access to targeted DNA and RNA platforms across regional health systems.

Competitive Landscape

The global Targeted DNA RNA Sequencing market is fragmented with numerous regional and mid-scale manufacturers operating alongside established genomics suppliers as adoption expands across clinical diagnostics and research workflows.

Illumina, Inc.: An emerging market player

Illumina, Inc. is a leading participant in the targeted DNA and RNA sequencing market, gaining wider visibility through its sequencing platforms and targeted panels that support high-throughput variant detection and gene expression profiling. By offering scalable workflows and a broad portfolio of assays, the company is strengthening its presence across clinical laboratories and research institutions worldwide.

List of Key and Emerging Players in Targeted DNA RNA Sequencing Market